- Home
- HHS vs SYRS Comparison
HHS vs SYRS Comparison
Compare HHS & SYRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- SYRS
- Stock Information
- Founded
- HHS 1923
- SYRS 2011
- Country
- HHS United States
- SYRS United States
- Employees
- HHS N/A
- SYRS N/A
- Industry
- HHS Advertising
- SYRS Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- SYRS Health Care
- Exchange
- HHS Nasdaq
- SYRS Nasdaq
- Market Cap
- HHS 55.0M
- SYRS 52.5M
- IPO Year
- HHS N/A
- SYRS 2016
- Fundamental
- Price
- HHS $7.33
- SYRS $1.99
- Analyst Decision
- HHS
- SYRS Strong Buy
- Analyst Count
- HHS 0
- SYRS 3
- Target Price
- HHS N/A
- SYRS $5.00
- AVG Volume (30 Days)
- HHS 14.3K
- SYRS 146.8K
- Earning Date
- HHS 11-07-2024
- SYRS 11-12-2024
- Dividend Yield
- HHS N/A
- SYRS N/A
- EPS Growth
- HHS N/A
- SYRS N/A
- EPS
- HHS N/A
- SYRS N/A
- Revenue
- HHS $187,093,000.00
- SYRS $4,149,000.00
- Revenue This Year
- HHS N/A
- SYRS N/A
- Revenue Next Year
- HHS $4.05
- SYRS $614.29
- P/E Ratio
- HHS N/A
- SYRS N/A
- Revenue Growth
- HHS N/A
- SYRS N/A
- 52 Week Low
- HHS $5.63
- SYRS $1.43
- 52 Week High
- HHS $8.87
- SYRS $8.17
- Technical
- Relative Strength Index (RSI)
- HHS 48.06
- SYRS 47.02
- Support Level
- HHS $6.66
- SYRS $1.90
- Resistance Level
- HHS $7.46
- SYRS $2.01
- Average True Range (ATR)
- HHS 0.30
- SYRS 0.11
- MACD
- HHS -0.00
- SYRS 0.04
- Stochastic Oscillator
- HHS 73.63
- SYRS 31.11
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.